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In this issue of the Journal, Liakos and coworkers1
report the results of a cross-sectional study aimed at
investigating the correlation of 24-hour blood pressure
(BP) and heart rate (HR) variability, as assessed by a
single session of 24-hour ambulatory BP monitoring,
with renal function in a large cohort of untreated,
uncomplicated essential hypertensive patients. In par-
ticular, the authors examined the influence of smoking
status on the relationship between BP/HR variability
and renal parameters including creatinine clearance,
estimated glomerular filtration rate, albumin-to-crea-
tinine ratio and urinary a1-microglobulin. Before
addressing the details of the study, available evidence
on this issue and related topics should be considered.
Strong evidence supports the view that cardiac and
extracardiac markers of hypertensive organ damage are
more closely related to home and ambulatory BP than to
office BP. Furthermore, numerous studies have shown
that organ damage also correlates with standard devi-
ation of 24-hour BP, suggesting that the adverse
consequences of hypertension on cardiovascular func-
tion and structure reflect both average 24-hour BP
elevations and BP variability. In a pioneering study
published in the early 1990s, Frattola and coworkers2
provided the first longitudinal evidence of the impact of
BP variability on target organ damage. Seventy-three
patients with essential hypertension who had their 24-
hour ambulatory BP monitored intra-arterially by the
Oxford technique were re-examined after 7 years or
more. According to multiple regression analysis, a
significant correlation was found between overall organ
damage score at follow-up evaluation (electrocardio-
graphic and/or echocardiographic left ventricular hyper-
trophy, retinopathy, and renal dysfunction) and initial
level of organ damage, long-term BP variability (among
half-hour standard deviation of 24-hour mean BP) at the
initial evaluation, and clinic BP at follow-up. This was
not the case for short-term BP variability (within half-
hour BP standard deviation), presumably because this
index represents a minor component of overall BP
variability.
After this seminal paper, increasing evidence has
accumulated on the association of BP variability with a
variety of manifestations of subclinical organ damage.
Several studies have shown that BP variability as
assessed by different parameters (ie, 24-hour BP vari-
ability, visit-to-visit variability) is related to increased
endothelial damage and arterial stiffness.3,4 Other
studies have reported that inflammatory markers of
vascular damage, such as C-reactive protein, soluble
E-selectin, tumor necrosis factor a, and interleukin 6
levels, are increased in patients with elevated 24-hour
BP variability.5 Finally, investigations performed in
different clinical settings have provided evidence that
increased BP variability, in addition to increased average
BP levels, is an independent predictor of development
and progression of renal disease as well as of cardio-
vascular events and mortality.6 In a post hoc analysis of
the Reduction of End Points in Non-Insulin-Dependent
Diabetes With the Angiotensin II Antagonist Losartan
Study and the Irbesartan Diabetic Nephropathy Trial,
including a total 2739 participants with type 2 diabetes
and nephropathy, McMullan and coworkers7 analyzed
the association of visit-to-visit systolic BP variability
with renal and cardiovascular morbidity and mortality
among individuals with diabetes and nephropathy.
A greater visit-to-visit variability of systolic BP (calcu-
lated from the standard deviation of systolic BP during 4
visits within 3 to 12 months post-randomization) was
independently associated with increased risk of the
composite renal disease endpoint and end-stage renal
disease, but not with the cardiovascular outcome. In a
cohort of 1618 patients with stage 2 to 5 chronic kidney
disease, visit-to-visit systolic BP variability was signifi-
cantly and independently related to baseline office BPs,
age, glucose, and estimated glomerular filtration rate
(eGFR). Both standard deviation of systolic BP and
variation coefficient of systolic BP were significant
predictors of the combined endpoint (death and incident
cardiovascular events) after adjusting for confounders.8
Seventy years ago, Levy and coworkers for the first
time documented an association between a faster HR
and cardiovascular disease.9 In the past 4 decades,
several authors have consistently shown that a higher
HR is a strong risk factor for cardiovascular morbidity
and mortality as well as for noncardiovascular death.
More recently, the clinical and prognostic value of HR
variability has been extensively investigated in patients
with coronary artery disease, congestive heart failure,
asymptomatic left ventricular dysfunction, valve dis-
ease, and essential hypertension. The majority of studies
have demonstrated that individuals with reduced or
abnormal HR variability have an increased likelihood of
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subclinical cardiac damage as well as a higher risk of
cardiovascular mortality. Various measures of HR
dynamics, such as time-domain, spectral, and nonlinear
measures of HR variability have been used for stratify-
ing cardiovascular risk. In the mid-1990s, Mandawat
and coworkers10 showed that patients with left ventric-
ular hypertrophy secondary to hypertension or aortic
valve disease had a higher left ventricular mass index
and reduced HR variability compared with controls.
Furthermore, in that study, an inverse relationship was
found between HR variability and left ventricular mass
index (r=0.478, P<.001). In one study evaluating right
ventricular remodeling, HR variability, and their inter-
action in untreated hypertensive patients, we found that
alterations in right ventricular structure, function, and
dynamics were associated with impaired HR variabil-
ity.11
Decreased HR variability associated with increased
risk of end-organ damage and cardiovascular events has
also been reported in the setting of chronic renal disease
over a wide range of ages in nondiabetic and type 1 and
2 diabetic populations.12
It has long been recognized that, in addition to day-
night BP changes, 24-hour BP and HR are characterized
by short-term variations that are more evident and
frequent during daytime but also present, although less
pronounced, during the nighttime period.
These variations are largely dependent on behavioral
activities, such as physical activity, job stress, and
smoking. Strong evidence supports the view that smok-
ing causes an imbalance of the autonomic nervous
system; in particular, tobacco smoke increases sympa-
thetic activity resulting in BP and HR elevation.13
The report by Liakos and coworkers1 provides a new
piece of evidence on the association between BP, HR,
and renal function in a large sample of adult untreated
essential hypertensive patients without diabetes and
renal insufficiency, stratified according to cigarette
smoking status. The prevalence of active smokers at
the time of examination was approximately 38%, and
about two thirds were men. BP and HR variability
were calculated as coefficients of variations derived
from 24-hour ambulatory recording. In the total
population, systolic 24-hour BP variability was inver-
sely related with creatinine clearance (CrCl) and eGFR;
this correlation failed to achieve statistical significance
after adjusting for age, sex, and smoking status. Similar
findings were obtained in the fraction of smoker
hypertensives. Systolic 24-hour BP variability showed
a positive relationship with albumin/creatinine ratio
and a1-microglobulin in the whole sample as well as in
the three smoking subgroups. It should be noted,
however, that average 24-hour systolic BP was more
strongly correlated with all above-mentioned renal
parameters than 24-hour BP variability. This important
finding conveys the concept that the magnitude of BP
variations during daily life has a lower impact on renal
damage than the absolute BP load in essential hyper-
tensive patients without comorbidities. A further
relevant result provided by Liakos and coworkers is
the notion that 24-hour HR variability was positively
correlated with renal function, a difference from 24-
hour BP variability. HR variability, indeed, was posi-
tively related to CrCl and eGFR, and inversely related
to albumin/creatinine ratio and a1-microglobulin; the
strength of this relationship was statistically significant
in the total sample as well as in all subgroups. This
suggests that reduced HR variability may be associated
with subtle alterations in renal function even in patients
without evidence of overt kidney disease. Interestingly,
this trend was more evident in current smokers than in
nonsmokers and former smokers. This observation is in
line with clinical studies showing a powerful correla-
tion between cigarette smoking and worsening renal
function in patients with hypertension, diabetes, and
chronic renal disease.14 Renal effects of nicotine
include transitory increases in BP paralleled by reduc-
tions in renal perfusion, increased generation of reac-
tive oxygen species, and activation of profibrotic
pathways. A few additional points deserve to be
discussed. First, average 24-hour HR, at variance from
24-hour variability, was found to be unrelated to renal
parameters in the total cohort as well as in smokers.
This negative finding is in keeping with previous
literature data. A lack of an independent association
between HR, derived from 48-hour ambulatory BP
monitoring, and markers of cardiac and extracardiac
target organ damage, such as left ventricular hypertro-
phy, carotid atherosclerosis, and microalbuminuria,
was shown by our group in 580 never-treated hyper-
tensive patients.15 Average 48-hour HR, indeed, was
similar in patients without organ involvement and in
those with one, two, or three markers of organ
damage. Second, the study by Liakos and coworkers
confirms and extends to a large cohort of uncompli-
cated hypertensives the notion that cigarette smoking
acts as a powerful risk factor for renal damage by
showing that a significant relationship exists between
the pack-years amount and subclinical renal impair-
ment.16 Third, the strengths of the present study are the
large, carefully selected population and the exclusion of
patients taking antihypertensive medications, as drug
treatment is known to affect the relationship between
BP/HR and organ damage. Finally, as recognized by the
authors, major limitations are represented by the cross-
sectional nature of the design and the estimate of HR
variability based only on data provided by ambulatory
BP monitoring rather than by 24-hour electrocardio-
graphic recording. Despite these limitations, the study
clearly supports the view that the impact of hyperten-
sion on renal function may depend on HR variability,
particularly in smokers.
Disclosures: The authors report no conflicts of interest. The authors alone are
responsible for the content and writing of the paper.
References
1. Liakos CI, Karpanou EA, Markou MI, et al. Correlation of 24-hour
blood pressure and heart rate variability to renal function parameters
The Journal of Clinical Hypertension Vol 17 | No 12 | December 2015 945
Commentary
in hypertensive patients: the effect of smoking. J Clin Hypertens
(Greenwich). 2015;DOI: 10.1111/jch.12640.
2. Frattola A, Parati G, Cuspidi C, et al. Prognostic value of 24-hour
blood pressure variability. J Hypertens. 1993;11:1133–1137.
3. Diaz KM, Veerabhadrappa P, KashemMA, et al. Visit to-visit and 24-
h blood pressure variability: association with endothelial and smooth
muscle function in African Americans. J Hum Hypertens.
2013;27:671–677.
4. Schillaci G, Bilo G, Pucci G, et al. Relationship between short-term
blood pressure variability and large-artery stiffness in human hyper-
tension: findings from 2 large databases. Hypertension. 2012;60:369–
377.
5. Tatasciore A, Zimarino M, Renda G, et al. Awake blood pressure
variability, inflammatory markers and target organ damage in newly
diagnosed hypertension. Hypertens Res. 2008;31:2137–2146.
6. Parati G, Xiu X, Ochoa JE. Clinical relevance of visit-to-visit blood
pressure variability: impact on renal outcomes. J Hum Hypertens.
2014;28:403–409.
7. McMullan CJ, Lambers Heerspink HJ, Parving HH, et al. Visit-to-
visit variability in blood pressure and kidney and cardiovascular
outcomes in patients with type 2 diabetes and nephropathy: a post hoc
analysis from the RENAAL study and the Irbesartan Diabetic
Nephropathy Trial. Am J Kidney Dis. 2014;64:714–722.
8. Mallamaci F, Minutolo R, Leonardis D, et al. Long-term visit-to-visit
office blood pressure variability increases the risk of adverse
cardiovascular outcomes in patients with chronic kidney disease.
Kidney Int. 2013;84:381–389.
9. Levy RL, White PD, Stroud WD, Hillman CC. Transient tachycardia:
prognostic significance alone and in association with transient
hypertension. JAMA. 1945;129:585–588.
10. Mandawat MK, Wallbridge DR, Pringle SD, et al. Heart rate
variability and left ventricular hypertrophy. Br Heart J.
1995;73:139–144.
11. Tadic M, Cuspidi C, Pencic B, et al. Relationship between right
ventricular remodeling and heart rate variability in arterial hyperten-
sion. J Hypertens. 2015;33:1090–1097.
12. Barletta GM, Flynn J, Mitsnefes M, et al. Heart rate and blood
pressure variability in children with chronic kidney disease: a report
from CKiD study. Pediatr Nephrol. 2014;19:1059–1065.
13. Middlekauff HR, Park J, Moheimani RS. Adverse effects of cigarette
smoking and non cigarette smoking exposure on the autonomic
nervous system. J Am Coll Cardiol. 2014;14:1740–1750.
14. Jain G, Jaimes EA. Nicotin signaling and progression of chronic
kidney disease in smokers. Biochem Pharmacol. 2013;86:1215–
1223.
15. Cuspidi C, Valerio C, Meani S, et al. Ambulatory heart rate and target
organ damage in never treated essential hypertensives. J Hum
Hypertens. 2007;22:89–95.
16. Noborisaka Y. Smoking and chronic kidney disease in healthy
populations. Nephrourol Mon. 2013;5:655–667.
946 The Journal of Clinical Hypertension Vol 17 | No 12 | December 2015
Commentary
